Scynexis Advances IV Antifungal SCY-247 into Phase 1 Trials
Event summary
- First participants dosed in Phase 1 SAD/MAD trial of IV SCY-247 on February 26, 2026.
- SCY-247 targets invasive candidiasis and fungal disease prophylaxis.
- FDA granted QIDP and Fast Track designations to SCY-247 in January 2026.
- Oral formulation of SCY-247 showed positive SAD/MAD data in September 2025.
The big picture
Scynexis' IV formulation of SCY-247 addresses critical gaps in treating severe fungal infections, particularly as antifungal resistance grows. The Phase 1 trial marks a pivotal step in expanding the company's antifungal pipeline beyond its licensed oral therapy, ibrexafungerp. Success here could position SCY-247 as a key player in combating drug-resistant infections, a market increasingly prioritized by regulators and healthcare systems.
What we're watching
- Trial Results
- Whether Phase 1 data for IV SCY-247 meets safety and efficacy benchmarks by end of 2026.
- Regulatory Pathway
- How Fast Track designation accelerates SCY-247's development timeline.
- Funding Strategy
- The pace at which Scynexis secures non-dilutive funding for SCY-247 program.
Related topics